WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017058896) TARGETS FOR TREATMENT OF HEPATOCELLULAR CARCINOMA CANCER AND METHODS RELATED THERETO
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/058896 International Application No.: PCT/US2016/054150
Publication Date: 06.04.2017 International Filing Date: 28.09.2016
IPC:
A61K 31/506 (2006.01) ,A61K 31/46 (2006.01) ,G01N 33/50 (2006.01) ,G01N 33/574 (2006.01)
Applicants: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE[US/US]; 10901 North Torrey Pines Road La Jolla, CA 92037, US
Inventors: KOH, Mei, Yee; US
POWIS, Garth; US
WARE, Carl, F.; US
Agent: HAILE, Lisa, A.; US
JACKSON, Blake; US
HIERHOLZER, Matthew, J.; US
HWANG, Pamela, E.; US
LIMBACH, Alan, A.; US
Priority Data:
62/233,77328.09.2015US
Title (EN) TARGETS FOR TREATMENT OF HEPATOCELLULAR CARCINOMA CANCER AND METHODS RELATED THERETO
(FR) CIBLES POUR LE TRAITEMENT DU CARCINOME HÉPATOCELLULAIRE ET PROCÉDÉS ASSOCIÉS
Abstract:
(EN) The present invention is based on the finding of a new tumor-suppressor role for HAF in immune cell function by preventing inappropriate HIF-1 activation in SART1+/" male mice. The findings identify RANTES (Regulated on Activation, Normal T cell Expressed and Secreted; also named Chemokine (C-C motif) ligand 5 (CCL5)) as a therapeutic target for CCL5 mediated disease, such as cancer. As such, the present invention provides, in part, a method for treating CCL5 mediated disease by administering an agent that inhibits CCL5/CCR5 signal transduction.
(FR) La présente invention concerne la découverte d'un nouveau rôle suppresseur de tumeur pour HAF dans la fonction cellulaire immune par la prévention de l'activation inappropriée de HIF-1 chez une souris mâle SART1+/". La découverte a permis d'identifier la RANTES (lymphocyte T normal régulé par activation, exprimé et sécrété, également nommée ligand de chémokine (motif C-C) 5 ou CCL5) en tant que cible thérapeutique pour une maladie induite par le CCL5, telle que le cancer. En tant que telle, la présente invention concerne, en partie, une méthode de traitement d'une maladie induite par le CCL5 par l'administration d'un agent qui inhibe la transduction de signal CCL5/CCR5.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)